ClinicaliQ Trial Snapshot
- A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or….
- Treatment being tested: Finerenone (a non-steroidal mineralocorticoid receptor antagonist) in combination with ACE inhibitors or angiotensin receptor blockers in children with chronic kidney disease and proteinuria, evaluating efficacy, safety, pharmacokinetics, and pharmacodynamics.
- Patient eligibility overview: Children diagnosed with chronic kidney disease who have proteinuria (protein leakage in urine) and are already receiving or eligible for ACE inhibitor or angiotensin receptor blocker therapy.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine. The kidneys filter waste and fluid from the blood to form urine. In children with CKD, the kidney´s filters do not work as well as they should. This can lead to accumulation of waste and fluid in the body and proteinuria. CKD can lead to other medical problems, such as high blood pressure, also known…
Eligibility Snapshot
- : * Participants must be 6 months to
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.